false
0001971532
0001971532
2025-08-07
2025-08-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 7, 2025
TELOMIR
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
| Florida |
|
001-41952 |
|
87-2606031 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File
Number) |
|
(IRS Employer
Identification No.) |
100
SE 2nd St, Suite 2000, #1009
Miami,
Florida
(Address of Principal Executive Offices)
Registrant’s
telephone number, including area code: (786) 396-6723
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| |
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| |
|
|
| |
☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| |
|
|
| |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
| |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common Stock, no par value
|
|
TELO |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01 Other Events
Telomir
Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration,
and Metabolic Dysfunction
New
data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes—highlighting its
potential to treat cancer, autoimmune conditions, neurodegeneration, and metabolic disorders through epigenetic modulation.
On
August 7, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target
the underlying mechanisms of aging and age-related diseases, today announced new in vitro data supporting the mechanism of action of
its lead drug candidate, Telomir-1.
In
a preclinical study conducted in collaboration with Eurofins Discovery, Telomir-1 was shown to inhibit three key histone demethylase
enzymes—JMJD3, FBXL10, and FBXL11—that regulate gene expression through epigenetic mechanisms. These enzymes function by
removing methyl groups from histones, effectively switching genes on or off. When overactive, they silence tumor suppressor genes and
activate pro-inflammatory or metabolic genes that contribute to disease.
Overactivation
of these enzymes can result from genetic amplification, chronic inflammation, and stress signals from the tumor microenvironment. These
factors can trigger persistent gene silencing or inappropriate activation of disease-promoting pathways, reinforcing their role in cancer,
immune disorders, and metabolic dysfunction.
Specifically:
| ● | JMJD3
is associated with inflammation, metastasis, and immune signaling dysregulation. It is overexpressed
in several cancers and chronic inflammatory diseases. |
| | | |
| ● | FBXL10
is known to drive aggressive cancers and promote resistance to therapy by maintaining cancer
cell stemness and suppressing tumor suppressors. |
| | | |
| ● | FBXL11
contributes to tumor proliferation and immune evasion and has been linked to both metabolic
dysfunction and neurodevelopmental disorders. |
By
inhibiting all three enzymes, Telomir-1 may help restore normal gene expression patterns in diseases characterized by epigenetic silencing,
making it a promising candidate across multiple high-burden indications.
Telomir-1’s
inhibition of these enzymes represents a potential breakthrough in the company’s effort to target upstream regulators of disease-related
gene silencing. The findings build upon previously disclosed results showing Telomir-1’s ability to reverse epigenetic silencing
of tumor suppressor genes such as STAT1 and TMS1 in PC3 xenograft prostate cancer models. In head-to-head comparisons, Telomir-1 demonstrated
more complete reactivation of STAT1 than either Paclitaxel or Rapamycin.
These
results provide important insight into Telomir-1’s mechanism of action and support its continued development across oncology and
other age-related therapeutic areas. The company is currently preparing to advance Telomir-1 into IND-enabling studies.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
TELOMIR PHARMACEUTICALS, INC. |
| |
|
| Dated: August 7, 2025 |
By: |
/s/
Erez Aminov |
| |
Name: |
Erez Aminov |
| |
Title: |
Chief Executive Officer |
